PT  - JOURNAL ARTICLE
AU  - Grint, Daniel J
AU  - Wing, Kevin
AU  - Williamson, Elizabeth
AU  - McDonald, Helen I
AU  - Bhaskaran, Krishnan
AU  - Evans, David
AU  - Evans, Stephen JW
AU  - Walker, Alex J
AU  - Hickman, George
AU  - Nightingale, Emily
AU  - Schultze, Anna
AU  - Rentsch, Christopher T
AU  - Bates, Chris
AU  - Cockburn, Jonathan
AU  - Curtis, Helen J
AU  - Morton, Caroline E
AU  - Bacon, Sebastian
AU  - Davy, Simon
AU  - Wong, Angel YS
AU  - Mehrkar, Amir
AU  - Tomlinson, Laurie
AU  - Douglas, Ian J
AU  - Mathur, Rohini
AU  - Blomquist, Paula
AU  - McKenna, Brian
AU  - Ingelsby, Peter
AU  - Croker, Richard
AU  - Parry, John
AU  - Hester, Frank
AU  - Harper, Sam
AU  - DeVito, Nicholas J
AU  - Hulme, Will
AU  - Tazare, John
AU  - Goldacre, Ben
AU  - Smeeth, Liam
AU  - Eggo, Rosalind M
TI  - Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England
AID  - 10.1101/2021.03.04.21252528
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.04.21252528
4099  - http://medrxiv.org/content/early/2021/03/08/2021.03.04.21252528.short
4100  - http://medrxiv.org/content/early/2021/03/08/2021.03.04.21252528.full
AB  - The B.1.1.7 variant of concern (VOC) is increasing in prevalence across Europe. Accurate estimation of disease severity associated with this VOC is critical for pandemic planning. We found increased risk of death for VOC compared with non-VOC cases in England (HR: 1.67 (95% CI: 1.34 - 2.09; P<.0001). Absolute risk of death by 28-days increased with age and comorbidities. VOC has potential to spread faster with higher mortality than the pandemic to date.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Medical Research Council MR/V015737/1. TPP provided technical expertise and infrastructure within their data centre pro bono in the context of a national emergency.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Health Research Authority (REC reference 20/LO/0651) and by the LSHTM Ethics Board (reference 21863).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are stored in a secure platform and cannot be shared directly. Please see opensafely.org for access information.